This study is the Company’s first reported results demonstrating that the anti-HER2 nanoparticles used in Imagion’s Magsense™ technology, which provide specific targeting of cancerous cells, may also have potential as an MR imaging contrast agent. The study shows MagSense nanoparticles may be equally effective as a multi-modal molecular imaging agint, generating detectable signals in two different imaging methods — superparamagnetic relaxometry (SPMR) and magnetic resonance imaging (MRI).
Download the poster.
Imagion presents MagSense® interim study results at breast cancer meeting
Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of